Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours
- PMID: 11748635
- DOI: 10.1002/path.1024
Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours
Abstract
Cancer is an epigenetic disease at the same level that it can be considered a genetic disease. In fact, epigenetic changes, particularly DNA methylation, are susceptible to change and are excellent candidates to explain how certain environmental factors may increase the risk of cancer. The delicate organization of methylation and chromatin states that regulates the normal cellular homeostasis of gene expression patterns becomes unrecognizable in the cancer cell. The genome of the transformed cell undergoes simultaneously a global genomic hypomethylation and a dense hypermethylation of the CpG islands associated with gene regulatory regions. These dramatic changes may lead to chromosomal instability, activation of endogenous parasitic sequences, loss of imprinting, illegitimate expression, aneuploidy, and mutations, and may contribute to the transcriptional silencing of tumour suppressor genes. The hypermethylation-associated inactivation affects virtually all of the pathways in the cellular network, such as DNA repair (hMLH1, BRCA1, MGMT, em leader), the cell cycle (p16(INK4a), p14(ARF), p15(INK4b), ...), and apoptosis (DAPK, APAF-1, ...). The aberrant CpG island methylation can also be used as a biomarker of malignant cells and as a predictor of their behaviour, and may constitute a good target for future therapies.
Copyright 2002 John Wiley & Sons, Ltd.
Similar articles
-
Epigenetic abnormalities in cutaneous squamous cell carcinomas: frequent inactivation of the RB1/p16 and p53 pathways.Br J Dermatol. 2006 Nov;155(5):999-1005. doi: 10.1111/j.1365-2133.2006.07487.x. Br J Dermatol. 2006. PMID: 17034532
-
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future.Oncogene. 2002 Aug 12;21(35):5427-40. doi: 10.1038/sj.onc.1205600. Oncogene. 2002. PMID: 12154405 Review.
-
DNA methylation and gene silencing in cancer: which is the guilty party?Oncogene. 2002 Aug 12;21(35):5380-7. doi: 10.1038/sj.onc.1205598. Oncogene. 2002. PMID: 12154400 Review.
-
Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors.Cancer Res. 2002 Aug 1;62(15):4519-24. Cancer Res. 2002. PMID: 12154064
-
A gene hypermethylation profile of human cancer.Cancer Res. 2001 Apr 15;61(8):3225-9. Cancer Res. 2001. PMID: 11309270
Cited by
-
Comprehensive Bioinformatic Investigation of TP53 Dysregulation in Diverse Cancer Landscapes.Genes (Basel). 2024 Apr 30;15(5):577. doi: 10.3390/genes15050577. Genes (Basel). 2024. PMID: 38790205 Free PMC article.
-
Discovery of novel DNA methylation biomarker panels for the diagnosis and differentiation between common adenocarcinomas and their liver metastases.Sci Rep. 2024 Feb 7;14(1):3095. doi: 10.1038/s41598-024-53754-1. Sci Rep. 2024. PMID: 38326602 Free PMC article.
-
SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer.Biomedicines. 2023 Oct 25;11(11):2884. doi: 10.3390/biomedicines11112884. Biomedicines. 2023. PMID: 38001885 Free PMC article.
-
The role of chromatin-modifying enzymes and histone modifications in the modulation of p16 gene in fumonisin B1-induced toxicity in human kidney cells.Mycotoxin Res. 2023 Aug;39(3):271-283. doi: 10.1007/s12550-023-00494-2. Epub 2023 Jun 16. Mycotoxin Res. 2023. PMID: 37328702
-
Epigenome-wide DNA methylation analysis of myasthenia gravis.FEBS Open Bio. 2023 Jul;13(7):1375-1389. doi: 10.1002/2211-5463.13656. Epub 2023 Jun 10. FEBS Open Bio. 2023. PMID: 37254650 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous